|Bid||0.0000 x 400000|
|Ask||0.0000 x 400000|
|Day's range||2.0110 - 2.0500|
|52-week range||1.8500 - 2.9590|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||6.36|
|Forward dividend & yield||0.09 (4.11%)|
|Ex-dividend date||15 Jun 2021|
|1y target est||N/A|
(Bloomberg) -- In the early days of the Covid-19 vaccine rollout, Chinese shots saved countless lives. They kick-started inoculation programs across Asia, Latin America and the Middle East, while richer countries hoarded scarce mRNA shots from Pfizer Inc. and Moderna Inc.Most Read from BloombergChristmas at Risk as Supply Chain ‘Disaster’ Only Gets WorseReshaped by Crisis, an ‘Anti-Biennial’ Reimagines ChicagoThis Is What Europe’s Green Future Looks LikeWhy the Gaza Strip May Be the City of the
The Delta variant is an increasing source of concern for health experts as vaccinations wane and the holiday weekend approaches in the U.S. Those at the highest risk are unvaccinated individuals and people living in pockets of states with low vaccination rates.
Chinese state-owned Sinopharm plans to inject 30 billion yuan ($4.6 billion) in assets into unit Beijing Tiantan Biological Products Corp Ltd to quickly get its fast-growing vaccine business on the public market, two people told Reuters. Sinopharm aims to begin the injection of six vaccine-focused biological products developers including makers of two COVID-19 vaccines into Shanghai-listed Tiantan in the coming weeks, said the people plus two other people with knowledge of the matter. The plan comes as China races to develop more homegrown COVID-19 vaccines to challenge Western rivals.